title: [Infantile haemangioma: When investigation is necessary and current therapeutic developments].
abstract: Infantile haemangioma (IH) is the most frequent benign tumour seen in children. In most cases, diagnosis is made chiefly on clinical grounds, and because the condition tends to subside naturally within several years and without any major sequelae, therapeutic abstention is the rule. However, a number of additional investigations may be necessary: where the clinical picture is atypical or potentially confusing, where the condition may affect adjacent or remote structures, in screening for associated anomalies in certain syndromal forms which practitioners must be able to recognise. Such investigations facilitate therapeutic indications for forms of haemangioma likely to lead to complications. The most important recent therapeutic development has been the discovery of the spectacular efficacy of beta-blockers (propranolol) upon the development kinetics of infantile haemangioma, greatly transforming the prognosis for these haemangiomas at risk.
authors.affiliation: Service de dermatologie, hôpital Robert-Debré, CHU de Reims, avenue du Général-Köenig, 51092 Reims cedex, France. Electronic address: ceschard@chu-reims.fr.
authors.forename: C
authors.initials: C
authors.lastname: Eschard
mesh_terms: D003937:Diagnosis, Differential; D006391:Hemangioma / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D006801:Humans; D007223:Infant; D011433:Propranolol / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D013577:Syndrome; D014665:Vasodilator Agents / Q000627:therapeutic use; D057832:Watchful Waiting
chemical_list: D014665:Vasodilator Agents; D011433:Propranolol
keywords: Haemangiomatosis; Hemangiomes infantiles; Hémangiomatose; Infantile haemangioma; Propranolol